Russell Investments Group Ltd. Has $110.44 Million Stake in IDEXX Laboratories, Inc. $IDXX

Russell Investments Group Ltd. reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,998 shares of the company’s stock after selling 9,367 shares during the quarter. Russell Investments Group Ltd. owned 0.22% of IDEXX Laboratories worth $110,441,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. Inceptionr LLC acquired a new position in shares of IDEXX Laboratories during the third quarter worth about $372,000. Schroder Investment Management Group grew its holdings in shares of IDEXX Laboratories by 2.4% during the third quarter. Schroder Investment Management Group now owns 323,305 shares of the company’s stock worth $203,863,000 after buying an additional 7,520 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management raised its position in IDEXX Laboratories by 5.5% in the 3rd quarter. Gerber Kawasaki Wealth & Investment Management now owns 497 shares of the company’s stock valued at $318,000 after buying an additional 26 shares during the last quarter. PFG Advisors raised its position in IDEXX Laboratories by 4.0% in the 3rd quarter. PFG Advisors now owns 12,032 shares of the company’s stock valued at $7,687,000 after buying an additional 461 shares during the last quarter. Finally, Pinnacle Associates Ltd. lifted its stake in IDEXX Laboratories by 2.4% in the 3rd quarter. Pinnacle Associates Ltd. now owns 1,209 shares of the company’s stock valued at $772,000 after acquiring an additional 28 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael G. Erickson sold 5,371 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued at $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on IDXX. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Barclays reduced their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. UBS Group decreased their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Up 0.3%

IDXX stock opened at $610.45 on Tuesday. The company has a market cap of $48.60 billion, a price-to-earnings ratio of 46.71, a P/E/G ratio of 3.69 and a beta of 1.66. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The business has a 50 day moving average price of $665.39 and a two-hundred day moving average price of $668.46. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.